Overall, our study demonstrates the efficacy of ACT with NeoAg-specific CD4+ T cells in a physiologically relevant tumor model and brings new insights to the use of similar approaches for adoptive immunotherapy of human cancer to empower more diverse, potent and durable antitumor immune responses. The gene discussed is CD4; the disease is cancer.